PT-141 (Bremelanotide)
Melanocortin agonist studied for sexual function and libido
Half-life
~2 hours
Typical Dose
1-2mg subcutaneous
Format
Injectable
Purity
≥98%
Overview
PT-141, also called Bremelanotide, is a melanocortin receptor agonist studied for sexual dysfunction in both men and women. FDA-approved as Vyleesi for premenopausal HSDD.
Mechanism
Agonist at melanocortin receptors (MC1R, MC3R, MC4R), activating central nervous system pathways involved in sexual arousal — a different mechanism than vascular drugs.
Researched benefits
- Libido and sexual function research
- Melanocortin pathway activation
- On-demand dosing
- Studied in both sexes
Frequently asked
Is PT-141 an approved drug?
Yes. PT-141 is bremelanotide, approved by the FDA as Vyleesi for hypoactive sexual desire disorder in premenopausal women. It is one of the few compounds in this category with a completed regulatory path.
How does PT-141 differ from PDE5 inhibitors?
Entirely different mechanism. Sildenafil and tadalafil act peripherally on vascular smooth muscle. PT-141 is a melanocortin receptor agonist acting centrally on MC4R in the brain, which is why it addresses desire rather than blood flow.
Why does PT-141 cause nausea and flushing?
Melanocortin receptors are widely distributed, so agonism is not confined to the pathway of interest. Nausea is the most commonly reported adverse effect in the Vyleesi trials, along with flushing and injection-site reactions.
How is PT-141 timed?
It is administered on demand rather than daily, typically at least 45 minutes before anticipated activity. Labeling limits use to a maximum of one dose in 24 hours and eight per month.
Ready to start your research
Get PT-141 (Bremelanotide) from Ascension Peptides
COA-verified, US-based, discreet shipping. Use code ENHANCED for 50% off your entire order.
Buy PT-141 (Bremelanotide) now